Cypherpunk Technologies (CYPH) vs Galectin Therapeutics (GALT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cypherpunk Technologies (CYPH) has outperformed Galectin Therapeutics (GALT) over the past year, gaining 387.2% versus a loss of 24.1%. Over five years, GALT leads with a +7.4% price change compared with -90.3% for CYPH. Galectin Therapeutics is the larger company by market cap ($369.1 million vs $296.9 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CYPH | GALT |
|---|---|---|
| Share price | $2.76 | $3.66 |
| Market cap | $296.89M | $369.11M |
| 1-day change | -9.67% | +1.10% |
| YTD return | +162.93% | -12.98% |
| 1-year return | +387.22% | -24.11% |
| 5-year return | -90.32% | +7.42% |
| P/E ratio (TTM) | 4.37 | — |
| EPS (TTM) | $0.63 | $-0.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.19 | $7.13 |
| 52-week low | $0.393 | $2.03 |
| Distance from 52-week high | -34.25% | -48.67% |
| Analyst consensus | none | none |
| Avg. price target upside | +77.86% | +200.55% |
| Average volume | 9.88M | 385.71K |
| Shares outstanding | 107.76M | 100.85M |
| Employees | 6 | 9 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CYPH has outperformed GALT by 411.3 percentage points over the past year.
About Cypherpunk Technologies
CYPH stock →Cypherpunk Technologies Inc., a privacy technology company, implements a digital asset strategy anchored by Zcash in the United States. The company is involved in identifying, developing, investing in, acquiring, and building privacy-enhancing technologies; and accumulating digital assets, such as ZCash.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
About Galectin Therapeutics
GALT stock →Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
CYPH vs GALT FAQ
Which is bigger, Cypherpunk Technologies or Galectin Therapeutics?
Galectin Therapeutics (GALT) is larger, with a market capitalization of $369.11M compared with $296.89M for Cypherpunk Technologies (CYPH).
Which stock has performed better over the past year, CYPH or GALT?
CYPH returned +387.22% over the past 12 months, compared with -24.11% for GALT (price return, excluding dividends). Past performance does not predict future results.
Are Cypherpunk Technologies and Galectin Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.